Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02905227 · ClinicalTrials.gov registry record · Phase 1

A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder

A Phase 1 study of Migraine, sponsored by Acorda Therapeutics.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
3
Study locations

NCT02905227: Completed Phase 1 study of Migraine, sponsored by Acorda Therapeutics.

NCT02905227 is a Phase 1 study of Migraine that has completed, run by Acorda Therapeutics. The registered enrollment target is 60 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02905227, a Phase 1 study of Migraine, has completed, sponsored by Acorda Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
3
Study locations

Study Summary

This study is an open-label, parallel group study to evaluate acute pulmonary safety and Pharmacokinetics (PK) of two doses, separated by 2 hours, of CVT-427 zolmitriptan inhalation powder in three groups of adults: those with asthma, those who smoke and healthy volunteers.

Conditions Studied

Interventions

  • DRUG CVT-427 (zolmitriptan inhalation powder)

Study Locations (3)

Massachusetts

  • Site #103 - North Dartmouth

Nebraska

  • Site #102 - Lincoln

Texas

  • Site #101 - Dallas

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2016-09
Est. Completion 2016-12
Phase Phase 1
Acorda Therapeutics

36 total trials

What the finished NCT02905227 record still lists

NCT02905227 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which CVT-427 (zolmitriptan inhalation powder) is the first listed.

NCT02905227 reports a single indexed study location in Massachusetts, Nebraska, Texas.

Frequently Asked Questions

What is clinical trial NCT02905227 about?

NCT02905227 is a clinical study titled "A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder". This study is an open-label, parallel group study to evaluate acute pulmonary safety and Pharmacokinetics (PK) of two doses, separated by 2 hours, of CVT-427 zolmitriptan inhalation powder in three groups of adults: those with asthma, those who smoke and healthy volunteers.

What is the current status of trial NCT02905227?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-09. Estimated completion is 2016-12.

What conditions does trial NCT02905227 study?

This clinical trial studies the following conditions: Migraine.

What interventions are being tested in trial NCT02905227?

The interventions under investigation include: CVT-427 (zolmitriptan inhalation powder) (DRUG).

Who is sponsoring clinical trial NCT02905227?

This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02905227 being conducted?

This trial has 3 study locations across Massachusetts, Nebraska, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02905227's enrollment target sits among peer trials

60 74th of 102 higher than 25 of 102 other Migraine trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02905227, the US trial registry maintained by the National Library of Medicine. NCT02905227 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.